RxDoctor Payments Data

John Hunter

Acute Care · Yukon, OKNPI 1568613065

Payments from drug & device makers

$1,432in general payments, 2019–2025

Across 58 payments — averaging $24.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$296
  • Abbott$144
  • AstraZeneca$121
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$118
  • Boehringer Ingelheim$111
  • Merck$96
  • plus $547 from 13 others

What the payments were for

  • Food & beverage$1,432100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,432 in reported general payments places this provider in the 65th percentile of 266 acute care providers in Oklahoma.

See all acute care providers in Oklahoma

Medicare billing

Part B allowed, 2024
$70,164
Medicare patients
651
Services billed
1,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$68,011
EntrestoSacubitril/Valsartan13$6,588
Metoprolol Succinate119$1,165
Ranolazine ErRanolazine21$1,019
Atorvastatin Calcium77$980
Nebivolol Hcl20$665
Diltiazem 24hr Er (Cd)Diltiazem Hcl24$621
Potassium Chloride68$592
Metolazone20$485
Carvedilol40$463
Torsemide12$399
Amlodipine Besylate63$381
Furosemide64$342
Lisinopril58$341
Valsartan13$299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$68,01194 claims
NovartisEntresto$16$6,58813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 266 acute care providers in Oklahoma.

Other acute care in Yukon

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →